Abstract:Abstract MAPK pathway activation is a feature of multiple tumor types. Drugging KRAS and BRAF, the two main oncogenic drivers in the MAPK pathway, has proven successful in the clinic. Inhibition of the downstream effectors, MEK and ERK, can also induce tumor regression. Despite this, many tumors are intrinsically resistant to MAPK pathway inhibitors, or acquire resistance under selective pressure to drug treatment. This creates a need for combination treatments to improve clinical responses. A synthetic lethal (SL) interaction between inhibition of the MAPK pathway and blockade of JNK-JUN signaling has recently been described1. Specifically, data from yeast genetics and CRISPR knockout experiments in human cells have identified MAP2K4 as a potential therapeutic target that could be combined with MAPK inhibitors. To date, however, no potent MAP2K4 inhibitors with in vitro and cellular selectivity against key anti-targets have been reported. Here, we describe the development of potent covalent inhibitors of MAP2K4 kinase activity. Biochemical and cell-based assays show that the compound(s) are selective for MAP2K4 versus anti-targets including MAP2K7 and ERK kinases. The combination of MAP2K4 and MEK/ERK inhibitors was effective in cell lines driven by MAPK signaling. These data provide the rationale for further development of MAP2K4 inhibitors to advance our understanding of this novel drug combination. References: 1. Xue Z, Vis DJ, Bruna A, Sustic T, van Wageningen S, Batra AS, et al. MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models. Cell Res. 2018; 28:719-29. Citation Format: Mark Wade, Emiliano Tamanini, Mathieu Unbekandt, Nicola Wallis, John Lyons, Joanne Munck, Andrew Woodhead, Patrick Schopf, Jessie Stow, Charlotte East, Mellissa Clark, Jeffrey St. Denis, Puja Pathuri. Targeting MAPK-driven tumors via inhibition of MAP2K4 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5902.

Considerations on the implementation of MAP4K4 inhibitors as cancer treatment

A review of non-classical MAPK family member, MAPK4: A pivotal player in cancer development and therapeutic intervention

Molecular Insights of MAP4K4 Signaling in Inflammatory and Malignant Diseases

MAP4K4 negatively regulates CD8 T cell-mediated antitumor and antiviral immunity.

Abstract 5902: Targeting MAPK-driven tumors via inhibition of MAP2K4

Overcoming radioresistance of breast cancer cells with MAP4K4 inhibitors

Dichotomous role of the serine/threonine kinase MAP4K4 in pancreatic ductal adenocarcinoma onset and metastasis through control of AKT and ERK pathways

MAPK4 Overexpression Promotes Tumor Progression Via Noncanonical Activation of AKT/mTOR Signaling

MAPK4 facilitates angiogenesis by inhibiting the ERK pathway in non-small cell lung cancer

Cooperative activation of PDK1 and AKT by MAPK4 enhances cancer growth and resistance to therapy

MAPK4 promotes triple negative breast cancer growth and reduces tumor sensitivity to PI3K blockade

Role of Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 Signaling in Liver and Metabolic Diseases

Mitogen-activated Protein Kinase Kinase 4 (MAP2K4) Promotes Human Prostate Cancer Metastasis.

Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases

RAS/MAPK Activation is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.

MAPK4 Silencing in Gastric Cancer Drives Liver Metastasis by Positive Feedback Between Cancer Cells and Macrophages.

Expression of MAP4K4 in Bladder Cancer and Its Biological Effect on Human Bladder Cancer T24 Cells

The MAPK pathway across different malignancies: A new perspective

A Fluorescence-Based Thermal Shift Assay Identifies Inhibitors of Mitogen Activated Protein Kinase Kinase 4

Mitogen-Activated Protein Kinase (MAPK): New Insights in Breast Cancer

Microtubule-affinity regulating kinase 4: A potential drug target for cancer therapy